Characteristic | Value |
---|---|
Age (n) | |
≤15 y | 41 (58.6%) |
>15 and ≤40 y | 25 (35.7%) |
>40 y | 4 (5.7%) |
Sex (n) | |
Male | 48 (68.6%) |
Female | 22 (31.4%) |
AJCC stage (n) | |
IIA | 24 (34.3%) |
IIB | 40 (57.1%) |
IV | 6 (8.6%) |
Tumor volume (cm3) | |
Median | 149 |
Range | 17–2,882 |
Location (n) | |
Distal femur | 35 (50.0%) |
Proximal tibia | 17 (24.3%) |
Proximal humerus | 6 (8.6%) |
Others | 12 (17.1%) |
Pattern on plain radiograph (n) | |
Lytic | 17 (24.3%) |
Blastic | 26 (37.1%) |
Mixed | 27 (38.6%) |
Pattern on MRI (n) | |
Concentric | 60 (85.7%) |
Longitudinal | 10 (14.3%) |
SUV1 | |
Median | 8.0 |
Range | 2.4–47.5 |
SUV2 | |
Median | 4.5 |
Range | 1.5–16.6 |
Time from first PET to initiation of chemotherapy | |
Median | 6 d |
Range | 1–13 d |
Time from end of chemotherapy to second PET | |
Median | 19 d |
Range | 16–22 d |
Time from second PET to surgery | |
Median | 2 d |
Range | 1–13 d |
Pathologic subtype (n) | |
Osteoblastic | 50 (71.4%) |
Chondroblastic | 13 (18.6%) |
Fibroblastic | 5 (7.1%) |
Other | 2 (2.9%) |
Type of surgery (n) | |
Amputation | 3 (4.3%) |
Limb salvage | 67 (95.7%) |
Histologic response (n) | |
Good | 33 (47.1%) |
Poor | 37 (52.9%) |
AJCC = American Joint Committee on Cancer.